Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse events

Author(s):
Wijn, D.H.; Groeneveld, G.H.; Vollaard, A.M.; Muller, M.; Wallinga, J.; Gelderblom, H.; Smit, E.F.
Published
2018
Publication type
Article / Letter to editor
Cancer immunotherapyImmune-related adverse even (irAE)Checkpoint inhibitorPD-1NivolumabInfluenza vaccineImmunocompromisedRespiratory tract infection
Date issued
2018-11-30
Language
English
Is part of
European Journal of Cancer (2018), Vol. 104, p. 182-187
hdl
1887/95705
doi
10.1016/j.ejca.2018.09.012